MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Each clinical milestone achieved by OCU400 brings us closer to providing a one-time treat ...

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Each clinical milestone achieved by OCU400 brings us closer to providing a one-time treat ...

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs ...

NEW YORK, June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and reminds investors of the June 10, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Conta ...

Ocugen, Inc. (OCGN) is having a phenomenal run in the year so far. Shares of the company have skyrocketed 209.6% year to date against the industry’s decline of 5.6%. The significant surge can be attributed to its encouraging pipeline progress. Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. Image Source: Zacks Investment Research The company is developing a modifier gene therapy platform designed to fulfill the significant ...

文章核心观点 - 公司Ocugen的财务报表从2020年5月8日至今存在重大错报 [1] - 公司Ocugen内部控制不足 [1] 公司概况 - 公司名称为Ocugen Inc. [1] - 公司股票代码为NASDAQ: OCGN [1] 诉讼相关 - 有股东提起集体诉讼 [1] - 诉讼指控公司做出了虚假和误导性陈述,或未披露重大不利信息 [1] - 投资者如果在2020年5月8日至2024年4月1日期间购买了公司股票并遭受重大损失,可以联系律师了解法律权利 [2] - 成为集体诉讼的首席原告的截止日期为2024年6月10日 [2] 律师事务所介绍 - 律师事务所名称为Holzer & Holzer, LLC [3] - 该律所在2021年和2022年被ISS评为证券诉讼领域顶级律所之一 [3] - 该律所专注于全国范围内的股东诉讼和衍生诉讼,多年来帮助受欺骗的股东追回了数亿美元的损失 [3] - 该律所的联系方式为电话(888)508-6832和电子邮箱cholzer@holzerlaw.com [4][5]

Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2 ArMaDa clin ...

Don't jump on the bandwaggon. Small biotech companies can be explosive. Massive gains above 100% in relatively short periods aren't that rare. That's what happened to Ocugen (OCGN 3.49%) this year. The company's shares are up 229% since January (as of this writing). As per usual, Ocugen owes this recent run to meaningful clinical progress. However, despite recent developments, the biotech remains far too risky for most investors. Here is why Ocugen's shares aren't worth the trouble right now. Promising pipe ...

BENSALEM, Pa., May 22, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Class Period: May 8, 2020 – April 1, 2024 Lead Plaintiff Deadline: June 10, 2024 Investors suffering losses on their Ocugen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-6 ...

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. "I'm very pleased to present OCU400 data amo ...